NCT03906695View on ClinicalTrials.gov

Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 15, 2019

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Lower-risk Myelodysplastic
Interventions
DRUG

ASTX727

oral decitabine 5mg + cedazuridine

DRUG

ASTX727

oral decitabine 5mg + cedazuridine

DRUG

ASTX727

oral decitabine 10mg + cedazuridine

DRUG

ASTX727

oral decitabine 20mg + cedazuridine

DRUG

ASTX727

oral decitabine 10mg + cedazuridine

Trial Locations (1)

Unknown

NTT Medical Center Tokyo, Tokyo

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY